EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy

Yi-Shao (Justus) Liu, Parth A Desai, Humera Khurshid, Anne C Chiang, Christine L Hann, Melissa L Johnson, Erik S Anderson, Rani Najdi, Jessie Wang, Xerxes Pundole

The Oncologist · 2026-11-05 · 31 (12)

DOI: 10.1093/oncolo/oyag434 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Platinum-etoposide (PE) chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor is the current first-line (1L) standard of care for extensive-stage small cell lung cancer (ES-SCLC). Real-world evidence describing outcomes across induction and maintenance phases remains limited. Patients and Methods This descriptive retrospective observational study used the US-based, electronic health record-derived deidentified Flatiron Health Research Database (January 2013-December 2024). Adults with pathologically confirmed ES-SCLC at initial diagnosis initiating 1L therapy were included. Patients were categorized by 1L regimen: PE plus a PD-L1 inhibitor (chemo-immunotherapy), PE alone, or other regimens. Maintenance was defined as at least 2 consecutive doses of post-induction PD-L1 inhibitor monotherapy. Real-world overall survival (rwOS) and progression-free survival (rwPFS) were estimated using the Kaplan-Meier method. Results Among 5863 1L patients, 2157 (36.8%) received chemo-immunotherapy, of whom ∼60% (1284/2157) received maintenance (atezolizumab, 85.7%; durvalumab 14.3%); 3376 (57.6%) received PE, and 330 (5.6%) other regimens. Median rwOS and rwPFS from 1L initiation were 8.1 months (95% CI, 8.0-8.3) and 5.1 months (95% CI, 5.0-5.2), respectively. From 1L initiation, patients who subsequently met the maintenance definition had median rwOS of 12.2 months. From maintenance initiation, median rwOS was 8.7 months (95% CI, 8.0-9.8) with atezolizumab and 9.3 months (95% CI, 8.0-11.5) with durvalumab. Conclusion In this large US real-world cohort, survival outcomes in 1L ES-SCLC patients were poor and appeared broadly comparable between atezolizumab and durvalumab. Only ∼60% of patients receiving chemo-immunotherapy subsequently received maintenance in routine clinical practice, underscoring substantial attrition before maintenance initiation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →